Hengrui and Heyi won the first imitation of ophthalmic drugs, and the 7 exclusive review varieties are eye-catching!

　　A few days ago, the CDE official website showed that Shijiazhuang Green Pharmaceutical's tobramycin eye drops, Zhongshan Wanhan Pharmaceutical's bromfenac sodium eye drops and other ophthalmic drugs have been accepted for production
.
Since the beginning of this year, 5 ophthalmic drugs have been approved.
The diquafosol sodium eye drops of Chengdu Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, and the lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical are the first imitations in China
.
According to data from Minet.
com, in the first quarter of 2022, the sales of terminal ophthalmic drugs in public hospitals in key provinces and cities increased by more than 7% year-on-year
.
TOP10 is released, Kanghong's blockbuster products have added indications, and Bayer has risen rapidly
.
At present, a total of 28 ophthalmic drugs (139 product specifications) have been submitted for production review, and Qilu Pharmaceutical, Jiangxi Kelun Pharmaceutical, Zhaoke (Guangzhou) ophthalmic drugs and other companies are sprinting for the first imitation
.
Eye medicine makes waves again! Hengrui and Heyi Pharmaceutical won the first imitation, and 7 varieties were exclusively reviewed.
Recently, the CDE official website showed that Shijiazhuang Green Pharmaceutical's Tobramycin eye drops, Hunan Xianshi Pharmaceutical | Zhejiang Thermo Pharmaceutical's sodium hyaluronate Both the eye drops and the bromfenac sodium eye drops of Zhongshan Wanhan Pharmaceutical were accepted as 4 types of imitations.
Among them, tobramycin eye drops have not been reviewed by any company, and Shijiazhuang Green Pharmaceuticals is expected to become the first company.
Over-evaluated companies.
.
.
Entering August, the ophthalmic drug market has made waves again, and 6 varieties (8 product specifications) have been accepted for production
.
Source of approvals for ophthalmic drug production since the beginning of this year: Minet.
com MED2.
0 China Drug Evaluation Database Quafosol sodium eye drops and lidocaine hydrochloride ophthalmic gel of Sichuan Heyi Pharmaceutical are the first imitations in China
.
In addition, Sichuan Heyi Pharmaceutical | Elements (Shanghai) Medical's Pranoprofen Eye Drops were approved as 3 types of imitations, and won the first review
.
Diquafosol sodium eye drops were developed by Inspire Pharmaceuticals in the United States.
In 1998, Japan's Santen Pharmaceutical signed a strategic cooperation agreement with Inspire to obtain the right to develop and sell the drug in Japan and other Asian countries.
Eye drops approved in China in 2017
.
In May of this year, the diquafossol sodium eye drops of Chengdu Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, were approved as imitation Category 4, and won the first imitation
.
Subsequently, Qilu Pharmaceutical and Yangzijiang Pharmaceutical Group were successively approved
.
Lidocaine hydrochloride ophthalmic gel is suitable for superficial examination of ophthalmic surgery and ophthalmic examinations
.
In March this year, Sichuan Heyi Pharmaceutical won the first imitation of the product
.
It is understood that the company is an enterprise integrating R&D, production and sales, with exclusive traditional Chinese medicine ophthalmic products as the access point, based on the development of a series of ophthalmic products.
At present, it has lidocaine hydrochloride ophthalmic gel, praprofen drops Eye drops, levofloxacin eye drops and other ophthalmic drugs
.
Source of over-evaluation of ophthalmic drugs: MED2.
0 China Drug Evaluation Database of Minet.
Up to now, 13 varieties (43 specifications) of ophthalmic drugs have been over-evaluated
.
Qilu Pharmaceutical's brimonidine tartrate eye drops, Chengdu Shengdi Pharmaceutical's tafluprost eye drops, Shenyang Xingqi eye drops cyclosporine eye drops (II), etc.
are all exclusive reviews
.
TOP10 is out! Kanghong's blockbuster products have added indications, and Bayer has rapidly climbed to the top 10 ophthalmic drug products in public hospitals in key provinces and cities in 2022Q1 Source: MINET.
com Competition Landscape of Public Hospitals in Key Provinces and Cities MINET.
com data shows that in the first quarter of 2022, public hospital terminals in key provinces and cities Ophthalmic drug sales climbed again, up more than 7% year-on-year
.
From the perspective of manufacturer structure, Novartis, Kanghong, and Bayer are among the top three
.
The TOP10 products have a high market concentration, with a total market share of more than 60%
.
In terms of growth rate, aflibercept intraocular injection solution grew the fastest, exceeding 50%, followed by polyvinyl alcohol eye drops and aescin and digitalis eye drops, which increased by 41.
48% and 34.
66% respectively.

.
Source of changes in the ranking of winning companies in the centralized procurement of ophthalmic drugs: The competition pattern of public hospitals in key provinces and cities of Minet Four varieties of eye drops, olopatadine hydrochloride eye drops, and moxifloxacin hydrochloride eye drops have been included in the collection
.
From the perspective of successful bidders, the market share has risen sharply, and the rankings have risen
.
2022Q1 Top 10 terminal ophthalmic drug brands in key provinces and cities.
Bercept intraocular injection solution ranks in the top three
.
The growth rate of diquafosol sodium eye drops has been amazing in recent years
.
Quarterly sales of Conbercept ophthalmic injection in public hospitals in key provinces and cities in recent years (unit: 10,000 yuan) Source: Minet According to the data of Minet.
com, in the first quarter of 2022, the sales of Conbercept ophthalmic injection in public hospitals in key provinces and cities rose steadily, with a year-on-year increase of more than 5%
.
In February this year, Kanghong Pharmaceutical issued an announcement that the supplementary application for Conbercept ophthalmic injection was approved by the State Food and Drug Administration, which agreed to extend the validity period of the product, change the registration standards and increase the packaging material suppliers, in order to continuously and stably produce high-quality products.
The products meet the market demand to provide guarantee
.
In May, Conbercept ophthalmic injection was approved for a fourth indication to increase macular edema secondary to retinal vein occlusion (RVO) (branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)) Indications for visual impairment caused by further meeting clinical drug needs
.
139 ophthalmic drugs are under review! Kelun, Qilu.
.
.
Initiated impact on ophthalmic drug production under review Source: Minet.
com MED2.
0 China Drug Evaluation Database Sodium eye drops and moxifloxacin hydrochloride eye drops are the most popular
.
In addition, brimonidine timolol eye drops, cyclosporine ophthalmic emulsion, lodoxamide tromethamine eye drops, flurbiprofen sodium eye drops and other domestic generic drugs have not yet been approved.
It involves Qilu Pharmaceutical, Jiangxi Kelun Pharmaceutical, Zhaoke (Guangzhou) Ophthalmic Drugs and other enterprises
.
From the perspective of enterprises, Qilu Pharmaceutical has the most, with 7; Tianjin Jinyao has 6, Shenyang Xingqi Eye Medicine and Zhongsheng Pharmaceutical have 5, Push Pharmaceutical, Huinland Pharmaceutical, Hefei Huawei Pharmaceutical, Hubei Yuanda Tiantianming Pharmaceutical and others have 4 each
.
Source: CDE official website, Minet database, etc.
Note: Minet's key provincial and municipal chemical drug terminal competition pattern database is based on the chemical drug procurement data of nearly 700 sample provincial and municipal public hospitals in 20+ provinces and cities.
The sample province and city sample hospital database for continuous monitoring of all drug categories; the above sales are calculated based on the average retail price of the product in the terminal
.
Eye medicine makes waves again! Hengrui and Heyi Pharmaceutical won the first imitation, and 7 varieties of exclusive review TOP10 were released! Kanghong’s blockbuster products have added indications, and Bayer has rapidly climbed to 139 ophthalmic drugs for production under review! Kelun, Qilu.
.
.
launched an attack